Liposome-supported enzymatic peritoneal dialysis

Pratsinis, Anna; Zuercher, Stefanie; Forster, Vincent; Fischer, E; Luciani, Paola; Leroux, Jean‐Christophe

doi:10.1016/j.biomaterials.2017.08.016

Cited by 21 publications

(20 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Conjugating small and large molecules to the polymersomeforming block copolymer can be used to encapsulate drugs and decorate polymersomes with targeting ligands. [77][78][79] Incorporating drugs using a biodegradable linker (analogously to drug-lipid conjugation for liposomes 80,81 ) may provide prolonged release kinetics due to an improved retention in the vesicle. 82 To increase the permeability of polymersomes for hydrophilic molecules and ions in a selective manner, transmembrane channel proteins can be incorporated into the membrane.…”

Section: Hydrophilic Drugs and Membrane Proteinsmentioning

confidence: 99%

Twenty-five years of polymersomes: lost in translation?

2020

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Hydrophilic Drugs and Membrane Proteinsmentioning

confidence: 99%

Twenty-five years of polymersomes: lost in translation?

2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…administration route was recently employed to improve the metabolism of overdosed ethanol following the administration of enzymatic L-LDC in the peritoneal cavity[84]. Depending on their lipid composition and size, liposomes can leave the peritoneal cavity relatively quickly and reach the blood compartment, achieving systemic exposure[85][86][87].…”

mentioning

confidence: 99%

Pharmacokinetics of lipid-drug conjugates loaded into liposomes

Signorell

Luciani

Brambilla

et al. 2018

European Journal of Pharmaceutics and Biopharmaceutics

Self Cite

View full text Add to dashboard Cite

Drugs that are neither lipophilic nor suitable for encapsulation via remote loading procedures are generally characterized by low entrapment efficiencies and poor retention in liposomes. One approach to circumvent this problem consists in covalently linking a lipid to the drug molecule in order to permit its insertion into the vesicle membrane. The nature of the conjugated lipid and linker, as well as the composition of the liposomal bilayer were found to have a profound impact on the pharmacokinetic properties and biodistribution of the encapsulated drugs as well as on their biological activity. This contribution reviews the past and recent developments on liposomal lipid-drug conjugates, and discusses important issues related to their stability and in vivo performance. It also provides an overview of the data that were generated during the clinical assessment of these formulations. The marketing authorization of the immunomodulating compound mifamurtide in several countries as well as the promising results obtained with the lipid prodrug of mitomycin C suggest that carefully designed liposomal formulations of lipid-drug conjugates is a valid strategy to improve a drug's pharmacokinetic profile and with that its therapeutic index and/or efficacy.

show abstract

“…Additionally, liposomes can be tailored for selectively removing specific endogenous and exogenous toxins by means of adjusting the lipid components, the liposome size, the length and degree of saturation of the lipid chain, the positive and negative charges, and the pH as well as other surface modifications (17,39). Notably, adding liposomes to conventional dialysis as a method to take up unwanted toxins has unique advantages in comparison with albumin and other alternative sorbent systems.…”

Section: Discussionmentioning

confidence: 99%

“…One of the main advantages is the fact that liposomes are made of natural materials, that is, lipids, and they can be easily synthesized. Additionally, liposomes can be tailored for selectively removing specific endogenous and exogenous toxins by means of adjusting the lipid components, the liposome size, the length and degree of saturation of the lipid chain, the positive and negative charges, and the pH as well as other surface modifications (17,39). Finally, the encapsulation of a wide variety of bioactive agents into liposomes has led to substantial interest in utilizing liposomes not only for their scavenging effect but also for their potential to achieve a therapeutic effect for a variety of diseases.…”

Section: Discussionmentioning

confidence: 99%

Increasing the removal of protein‐bound uremic toxins by liposome‐supported hemodialysis

Shi

Wang

et al. 2018

Artificial Organs

View full text Add to dashboard Cite

Protein‐bound uremic toxins (PBUTs) accumulate at high plasma levels and cause various deleterious effects in end‐stage renal disease patients because their removal by conventional hemodialysis is severely limited by their low free‐fraction levels in plasma. Here, we assessed the extent to which solute removal can be increased by adding liposomes to the dialysate. The uptake of liposomes by direct incubation in vitro showed an obvious dose‐response relationship for p‐cresyl sulfate (PCS) and indoxyl sulfate (IS) but not for hippuric acid (HA). The percent removal of both PCS and IS but not of HA was gradually increased with the increased concentration of liposomes in a rapid equilibrium dialysis setup. In vitro closed circulation showed that adding liposomes to the dialysate markedly increased the dialysances of PBUTs without greatly altering that of urea and creatinine. In vivo experiments in uremic rats demonstrated that adding liposomes to the dialysate resulted in higher reduction ratios (RRs) and more total solute removal (TSR) for several PBUTs compared to the conventional dialysate, which was approximately similar to the addition of bovine serum albumin to the dialysate. These findings highlight that as an adjunct to conventional hemodialysis, addition of liposomes to the dialysate could significantly improve the removal of protein‐bound uremic solutes without greatly altering the removal of small, water‐soluble solutes.

show abstract

Liposome-supported enzymatic peritoneal dialysis

Cited by 21 publications

References 54 publications

Twenty-five years of polymersomes: lost in translation?

Twenty-five years of polymersomes: lost in translation?

Pharmacokinetics of lipid-drug conjugates loaded into liposomes

Increasing the removal of protein‐bound uremic toxins by liposome‐supported hemodialysis

Contact Info

Product

Resources

About